Septerna reports Q4 EPS (24c), consensus (22c)

Reports Q4 revenue $24.12M, consensus $15.56M. “We made significant strides advancing our pipeline in the past year, and 2026 has already delivered a meaningful milestone with positive Phase 1 results for SEP-631,” said Jeffrey Finer, chief executive officer and co-founder of Septerna (SEPN). “These results demonstrate clinical proof-of-mechanism and validate the ability of our Native Complex Platform to uncover novel mechanisms of action and rapidly generate differentiated oral small molecules for historically challenging GPCRs. With SEP-479 approaching Phase 1 initiation in the coming months, SEP-631 poised for Phase 2 development in the second half of the year, and additional programs progressing behind them, we believe 2026 will be a year of strong progress for Septerna and for the patients we are committed to serving.”